Morphic Therapeutic said Tuesday that an experimental oral medicine induced complete remissions in 26% of patients with ulcerative colitis — achieving the goal of a mid-stage study.
More importantly, the study results suggest the Morphic drug, taken as a twice-daily pill, has the potential to match the efficacy and tolerability of Entyvio, an IV-administered treatment and a $5 billion-plus commercial blockbuster for its maker, Takeda.
The Morphic drug, called MORF-057, has years of clinical studies ahead, but just the prospect of an “oral Entyvio” could transform the company into an attractive takeover target for large pharmaceutical companies eager to acquire smaller developers of medicines for immune-based diseases.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
